 |
366 Diseases |  |
40 Trials |
|
40 Trials |  |
1661 News |  |
| «12...11121314151617181920212223» |
- Oncaspar liquid (pegaspargase) / Servier, Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy: Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 25, 2013
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting
- RG4733 / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy, Metastases: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2013
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Enrollment closed: Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Mar 25, 2013
P1/2, N=144, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy, Metastases: Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) (clinicaltrials.gov) - Mar 13, 2013
P1, N=180, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=140 --> 180
- Torisel (temsirolimus) / Pfizer
Trial suspension, Combination therapy: A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma (clinicaltrials.gov) - Mar 10, 2013
P1, N=30, Suspended, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
N=140 --> 180 Recruiting --> Suspended
- perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Enrollment closed: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - Mar 3, 2013
P1/2, N=92, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Active, not recruiting
- | Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer
New P2 trial, Metastases: A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus (clinicaltrials.gov) - Feb 21, 2013
P2, N=41, Recruiting, Sponsor: Seoul National University Hospital
- dovitinib (TKI258) / Novartis, Oncoheroes
New P2 trial: DILIGENCE-1: 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC (clinicaltrials.gov) - Feb 13, 2013
P2, N=30, Active, not recruiting, Sponsor: Auckland District Health Board
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion, Metastases: TORAVA: Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Feb 13, 2013
P2, N=160, Completed, Sponsor: Centre Leon Berard
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | lenalidomide / Generic mfg.
Trial completion: Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males (clinicaltrials.gov) - Feb 11, 2013
P1, N=31, Completed, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment closed, Metastases: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 4, 2013
P2, N=330, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Active, not recruiting
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Torisel (temsirolimus) / Pfizer
Enrollment closed, Surgery, Metastases: Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Feb 3, 2013
P2, N=70, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- || Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) (clinicaltrials.gov) - Feb 3, 2013
P1, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
New P4 trial, P4 data, Metastases: A Post Marketing Surveillance As Required By Philippine Food And Drug Administration (clinicaltrials.gov) - Jan 30, 2013
P4, N=0, Withdrawn, Sponsor: Pfizer
- ||||||| Torisel (temsirolimus) / Pfizer, sunitinib / Generic mfg.
Trial completion, Metastases: INTORSECT: Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (clinicaltrials.gov) - Jan 30, 2013
P3, N=512, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Enrollment change, Surgery, Metastases: Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function (clinicaltrials.gov) - Jan 28, 2013
P1, N=130, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=26 --> 130
- Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy, Metastases: Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 28, 2013
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=26 --> 130 Completed --> Active, not recruiting
- ||| Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Trial completion, Combination therapy: Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors (clinicaltrials.gov) - Jan 27, 2013
P1, N=63, Completed, Sponsor: Puma Biotechnology, Inc.
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial termination: CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 22, 2013
P2, N=60, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.
- Torisel (temsirolimus) / Pfizer
Enrollment change, Circulating tumor cells, Tumor cell, Metastases: Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 22, 2013
P2, N=11, Terminated, Sponsor: Duke University
Completed --> Terminated; Administratively complete. N=20 --> 11
- || Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Enrollment change, Stroma, Metastases: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=1600, Recruiting, Sponsor: Pfizer
N=20 --> 11 N=415 --> 1600
- Torisel (temsirolimus) / Pfizer
Trial termination, Metastases: Temsirolimus (Torisel (clinicaltrials.gov) - Jan 13, 2013
P2, N=13, Terminated, Sponsor: New Mexico Cancer Care Alliance
N=415 --> 1600 Active, not recruiting --> Terminated; High patient withdrawal rate
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Temsirolimus (Torisel (clinicaltrials.gov) - Jan 13, 2013
P2, N=13, Terminated, Sponsor: New Mexico Cancer Care Alliance
Active, not recruiting --> Terminated; High patient withdrawal rate N=37 --> 13
- Torisel (temsirolimus) / Pfizer
Trial termination, Combination therapy: Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jan 10, 2013
P1, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
N=37 --> 13 Completed --> Terminated
- Torisel (temsirolimus) / Pfizer
Enrollment change: Erlotinib and Temsirolimus for Solid Tumors (clinicaltrials.gov) - Jan 10, 2013
P1, N=38, Recruiting, Sponsor: Washington University School of Medicine
Completed --> Terminated N=25 --> 38
- Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Jan 10, 2013
P2, N=74, Suspended, Sponsor: National Cancer Institute (NCI)
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Trial completion, Surgery, Metastases: Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 10, 2013
P2, N=120, Completed, Sponsor: National Cancer Institute (NCI)
N=25 --> 38 Active, not recruiting --> Completed
- Signifor LAR (pasireotide long acting release) / Recordati
Trial withdrawal, Combination therapy: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus (clinicaltrials.gov) - Jan 7, 2013
P2, N=0, Withdrawn, Sponsor: Milton S. Hershey Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change, Combination therapy: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus (clinicaltrials.gov) - Jan 7, 2013
P2, N=0, Withdrawn, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Withdrawn N=40 --> 0
- Torisel (temsirolimus) / Pfizer
Biomarker, Trial completion: Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse (clinicaltrials.gov) - Jan 6, 2013
P2, N=15, Completed, Sponsor: Jonsson Comprehensive Cancer Center
N=40 --> 0 Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial termination: Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer (clinicaltrials.gov) - Jan 3, 2013
P1, N=24, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Withdrawn --> Terminated
- Torisel (temsirolimus) / Pfizer
Enrollment closed: Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 20, 2012
P1/2, N=12, Active, not recruiting, Sponsor: Washington University School of Medicine
Withdrawn --> Terminated Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Enrollment open, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Dec 17, 2012
P1, N=114, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial termination, Metastases: Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 12, 2012
P1/2, N=11, Terminated, Sponsor: University of Tennessee Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 12, 2012
P1/2, N=11, Terminated, Sponsor: University of Tennessee Cancer Institute
Recruiting --> Terminated N=56 --> 11
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Torisel (temsirolimus) / Pfizer
Trial initiation date, Metastases: Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV (clinicaltrials.gov) - Dec 10, 2012
P2, N=35, Terminated, Sponsor: National Cancer Institute (NCI)
N=56 --> 11 Initiation date: Jun 2010 --> Oct 2010
- Torisel (temsirolimus) / Pfizer
Biomarker, Enrollment change, Metastases: Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Dec 10, 2012
P=N/A, N=11, Active, not recruiting, Sponsor: St. Joseph's Healthcare Hamilton
Initiation date: Jun 2010 --> Oct 2010 N=20 --> 11
- Torisel (temsirolimus) / Pfizer
Trial completion, Surgery, Metastases: Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function (clinicaltrials.gov) - Dec 6, 2012
P1, N=130, Completed, Sponsor: National Cancer Institute (NCI)
N=20 --> 11 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene, Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 14, 2012
P1, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=30 --> 0
- Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Study of Temsirolimus, Topotecan, and Bortezomib (clinicaltrials.gov) - Nov 11, 2012
P1, N=80, Completed, Sponsor: M.D. Anderson Cancer Center
N=30 --> 0 Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (clinicaltrials.gov) - Nov 7, 2012
P1, N=69, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=25 --> 69
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment open: Doxil, Bevacizumab and Temsirolimus Trial (clinicaltrials.gov) - Oct 30, 2012
P1, N=206, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=25 --> 69 Active, not recruiting --> Recruiting
- Torisel (temsirolimus) / Pfizer
Trial withdrawal, Metastases: Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer (clinicaltrials.gov) - Oct 29, 2012
P2, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Active, not recruiting --> Recruiting Recruiting --> Withdrawn
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer (clinicaltrials.gov) - Oct 29, 2012
P2, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Recruiting --> Withdrawn N=38 --> 0
- |||| Votrient (pazopanib) / Novartis, Torisel (temsirolimus) / Pfizer
Enrollment open: Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Oct 23, 2012
P2, N=90, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=38 --> 0 Not yet recruiting --> Recruiting
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial initiation date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Oct 23, 2012
P1, N=114, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Initiation date: Jul 2012 --> Dec 2012
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment (clinicaltrials.gov) - Oct 23, 2012
P1, N=39, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2012 --> Dec 2012 Active, not recruiting --> Completed
- | lenalidomide / Generic mfg.
New P1 trial: Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males (clinicaltrials.gov) - Oct 22, 2012
P1, N=31, Completed, Sponsor: Celgene Corporation
- Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer and Liver Dysfunction (clinicaltrials.gov) - Oct 13, 2012
P1, N=25, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Enrollment closed: Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors (clinicaltrials.gov) - Oct 9, 2012
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting